Entries |
Document | Title | Date |
20080207610 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION - Disclosed are novel isoflavone derivatives having the structure of Formula I | 08-28-2008 |
20080242664 | DNA-PK INHIBITORS - A compound of formula I: | 10-02-2008 |
20080318944 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS - Disclosed are N-aroyl cyclic amine derivatives having the formula: | 12-25-2008 |
20080318945 | Novel Compounds - This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted piperazines, according to Formula I | 12-25-2008 |
20090005375 | ACETYL COENZYME A CARBOXYLASE INHIBITORS - The present invention relates to acetyl coenzyme-A carboxylase (“ACC”) inhibiting compounds of the formula | 01-01-2009 |
20090012081 | Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells - An agent for promoting the proliferation or differentiation of a stem cell and/or neural progenitor cell, comprising a compound represented by Formula: | 01-08-2009 |
20090036442 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS - Disclosed are N-aroyl cyclic amine derivatives having the formula: | 02-05-2009 |
20090048247 | CONDENSED ISOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE TYPE - IV - The present invention relates to isoxazoline derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases in a patient, particularly in humans. The present invention also relates to processes for the preparation of disclosed compounds, as well as pharmaceutical compositions thereof, and their use as phosphodiesterase (PDE) type IV inhibitors. | 02-19-2009 |
20090069316 | NOVEL QUINOLINE DERIVATIVES - The invention relates to compounds represented by Formula (I): | 03-12-2009 |
20090076000 | DEUTERIUM-ENRICHED MYCOPHENOLATE MOFETIL - The present application describes deuterium-enriched mycophenolate mofetil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090088427 | Treatment of Vascular, Autoimmune and Inflammatory Diseases Using Low Dosages of IMPDH Inhibitors - The disclosure provides methods and compositions for treating a vascular, autoimmune, and/or inflammatory disease, or a condition associated therewith, with a dose of an inosine monophosphate dehydrogenase (IMPDH) inhibitor effective to treat the vascular, autoimmune and/or inflammatory disease, or associated condition but that does not produce immunosuppression sufficient to reduce the risk of allograft rejection. These lower doses of the immunosuppressant avoid the adverse consequences of severe immunosuppression while providing effective treatment of the vascular, autoimmune and/or inflammatory disease. | 04-02-2009 |
20090099169 | Benzofuran Compounds As EP1 Receptor Antagonists - Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: | 04-16-2009 |
20090124613 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders - The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders. | 05-14-2009 |
20090131427 | Costunolide Derivatives - Disclosed are methods for inhibiting TNFα expression, IL-1β expression, iNOS expression, and NF-κB activity and methods for treating autoimmune disease, cancer, or atherosclerosis with a compound of the following formula: | 05-21-2009 |
20090192152 | Novel Antigiardial Agents and Methods of Use Thereof - The present invention provides a method of preventing or treating one or more of the following medical conditions, or treating symptoms of one or more of the following medical conditions: amebic infections, giardiasis, estrogen deficient states, osteoporosis, cardiovascular heart disease, high cholesterol levels, hyperlipidemia, cancer by administering to a subject having, or predisposed to, one or more of the conditions, a therapeutically effective amount of a compound of the present invention and a pharmaceutically acceptable carrier. | 07-30-2009 |
20090203685 | ANTI-PROLIFERATIVE COMPOUNDS FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF - The present invention is directed to molecules deriving from a 3-aryl-coumarine or 3-aryl-quinolin-2-one and having potent anti-proliferative and/or cytotoxic activity, especially against tumoral cells. The present invention also concerns the uses of these molecules in therapeutic application, for the treatment of different cancers. The invention also discloses the use of said compound for the manufacture of a medicament for treating cancer. The invention also concerns a process for inhibiting cell proliferation comprising contacting said cells with a compound of the invention. | 08-13-2009 |
20090203686 | Aminoalkyl-Amidomethyl-Substituted 2-(4-Sulphonylamino)- 3-Hydroxy-3,4-Dihydro-2H-Chroman-6-yl Derivatives - Compounds corresponding to formula I, | 08-13-2009 |
20090209532 | PHARMACEUTICAL COMPOUNDS - Compounds of formula (I) exhibit COMT enzyme inhibiting activity and are thus useful as COMT inhibitors. | 08-20-2009 |
20090209533 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION - Disclosed are novel isoflavone derivatives having the structure of Formula I | 08-20-2009 |
20090215767 | ISOFLAVONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME - An isoflavone derivative is provided. The isoxazole derivative has following formula: | 08-27-2009 |
20090215768 | ISOXAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME - An isoxazole derivative is provided. The isoxazole derivative has following formula: | 08-27-2009 |
20090221572 | 4,5,6,7-TETRAHYDROBENZO[B]THIOPHENE DERIVATIVES AND THEIR USE AS SIGMA RECEPTOR LIGANDS - The present invention relates to compounds having pharmacological activity towards the sigma (σ) receptor, and more particularly to some 4, 5, 6, 7 tetrahydrobenzo[b]thiophene derivatives, wherein n is selected from 0, 1, 2, 3 or 4; m is selected from 0, 1 or 2; the dotted line represents either a single or a double bond; to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and prophylaxis, in particular for the treatment of psychosis. | 09-03-2009 |
20090239860 | NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE - The present invention provides compounds represented by general formula (I): | 09-24-2009 |
20090281097 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND - The object of the present invention is to provide a compound having an ACC inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and has superior properties such as efficacy, duration of activity, specificity, low toxicity and the like. | 11-12-2009 |
20090286780 | 2-OXOCHROMENE DERIVATIVES - To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. | 11-19-2009 |
20100029639 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF - Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local anesthesia. | 02-04-2010 |
20100029640 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases - Disclosed herein are methods of treating neurodegenerative diseases comprising administering to the subject a compound having the structure: | 02-04-2010 |
20100056512 | PYRIMIDINE COMPOUNDS - Pyrimidine compounds of the following formula: | 03-04-2010 |
20100069381 | GSK-3BETAINHIBITOR - For the purpose of providing a GSK-3β inhibitor containing an oxadiazole compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3β-related pathology or disease, the present invention provides a GSK-3β inhibitor containing a compound represented by the formula (I): | 03-18-2010 |
20100087430 | NOVEL BENZOFURAN POTASSIUM CHANNEL BLOCKERS AND USES THEREOF - The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of K | 04-08-2010 |
20100087431 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS - The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer. | 04-08-2010 |
20100125073 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERS OF THE CENTRAL NERVOUS SYSTEM - The present invention relates to benzofuran and benzothiophene derivatives and compositions containing such compounds for the production of medicaments for the treatment of cancers of the central nervous system as monotherapy or combination with other agents. | 05-20-2010 |
20100144729 | COUMARIN DERIVATIVES - A compound of formula (I) wherein R | 06-10-2010 |
20100197685 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF - The present invention relates to the novel benzofuran derivatives, the preparation thereof and the composition comprising the same. The benzofuran derivatives of the present invention showed potent inhibiting activity of beta-amyloid aggregation and cell cytotoxicity resulting in stimulating the proliferation of neuronal cells as well as recovering activity of memory learning injury caused by neuronal cell injury using transformed animal model with beta-amyloid precursor gene, therefore the compounds can be useful in treating or preventing cognitive function disorder. | 08-05-2010 |
20100197686 | THERAPEUTIC COMPOUNDS - The invention provides compounds of Formula (I) and (IV): as described herein, as well as salts thereof. The compounds have anti-cancer properties and/or chemosensitization properties. | 08-05-2010 |
20100204220 | HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS - Heterocyclic compounds which modulate cannabinoid receptors are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as modulators of cannabinoid receptors and processes for synthesizing these compounds are also described herein. | 08-12-2010 |
20100286141 | Compositions and Methods for Identifying Agents Which Modulate PTEN Function and PI-3 Kinase Pathways - Methods are provided for the identification, biochemical characterization and therapeutic use of agents which impact PTEN, p53, PI-kinase and AKT mediated cellular signaling. | 11-11-2010 |
20110021522 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 - The present invention provides compounds as activators of procaspases 3, 6 and/or 7 and related derivatives, pharmaceutical compositions thereof, methods for their use, and methods for preparing these compounds. In one aspect, the compounds are useful for treating cancers and neoplastic diseases. | 01-27-2011 |
20110077244 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE - The present invention relates to synthetic studies of a novel thiophenediamine derivative having a urea structure and to finding pharmaceutical actions thereof. The present invention provides a compound represented by the following general formula (1) or a salt thereof. In the formula (1), R | 03-31-2011 |
20110105495 | CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF - A compound of Formula (I) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof, wherein R | 05-05-2011 |
20110118257 | NOVEL KINASE MODULATORS - The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them. | 05-19-2011 |
20110144101 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS - The present invention provides methods for the use of compounds having formula (I) in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis, wherein R | 06-16-2011 |
20110207729 | BICYCLIC ACYLGUANIDINE DERIVATIVE - An object of the present invention is to provide a novel and excellent agent for treating or preventing dementia, schizophrenia, and the like, based on the serotonin 5-HT | 08-25-2011 |
20110207730 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF - Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local anesthesia. | 08-25-2011 |
20110212958 | FATTY ACID RALOXIFENE DERIVATIVES AND THEIR USES - The invention relates to fatty acid raloxifene derivatives; compositions comprising an effective amount of a fatty acid raloxifene derivative; and methods for treating osteoporosis or preventing invasive breast cancer in postmenopausal women comprising the administration of an effective amount of a fatty acid raloxifene derivative. | 09-01-2011 |
20110245244 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS - Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are activators of PPARδ and should be useful for treating conditions mediated by the same. | 10-06-2011 |
20110257174 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS - Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent. | 10-20-2011 |
20110269755 | COMPOSITIONS AND METHODS FOR TREATING VASCULAR, AUTOIMMUNE, AND INFLAMMATORY DISEASES - The disclosure provides compositions and methods for the treatment of vascular, autoimmune, and inflammatory diseases using a combination of an inosine monophosphate dehydrogenase (IMPDH) inhibitor and a HMG CoA reductase inhibitor. | 11-03-2011 |
20110306608 | COMPOSITIONS AND METHODS FOR TREATING VASCULAR, AUTOIMMUNE AND INFLAMMATORY DISEASES - The disclosure provides methods and compositions for the treatment of vascular, autoimmune and inflammatory diseases using a combination of an inosine monophosphate dehydrogenase (IMPDH) inhibitor and a HMG CoA reductase inhibitor. | 12-15-2011 |
20120022062 | Flavanoid Compounds and Process for Preparation Thereof - The present invention relates to flavanoid compounds of general formula (X | 01-26-2012 |
20120142682 | ANTIVIRULENCE COMPOUNDS INHIBITING BACTERIAL MONO-ADP-RIBOSYLTRANSFERASE TOXINS - Compounds that inhibit bacterial virulence factors from the mono-ADP-ribosyltransferase (mART) family of toxins have been identified that are not toxic to cells or the producing bacterial pathogen. These compounds have great potential as antivirulence agents for treating many bacterial infections and disease states. | 06-07-2012 |
20120238566 | USE OF CELL AUTOPHAGY (TYPE II CELL APOPTOSIS) INHIBITORS - Use of cell autophagy (type II cell apoptosis) inhibitors for preventing and/or treating avian influenza, injury of lungs caused by avian influenza virus or nanometer materials. The cell autophagy (type II cell apoptosis) inhibitors are selected from 3-methyladenine, SB203580, LY294002, and or wortmannin. The injury of lungs includes acute respiratory distress syndrome. The avian influenza virus is H5N1, H5N2 or H9N2 avian influenza virus. The nanometer materials include PAMAM G3, G4, G5, G5.5, G6, G7, or G8. | 09-20-2012 |
20120238567 | 4,5,6,7-TETRAHYDROBENZO[B]THIOPHENE DERIVATIVES AND THEIR USE AS SIGMA RECEPTOR LIGANDS - The present invention relates to compounds having pharmacological activity towards the sigma (σ) receptor, and more particularly to some 4, 5, 6, 7 tetrahydrobenzo[b]thiophene derivatives, wherein n is selected from 0, 1, 2, 3 or 4; m is selected from 0, 1 or 2; the dotted line represents either a single or a double bond; to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and prophylaxis, in particular for the treatment of psychosis. | 09-20-2012 |
20120245165 | NOVEL BENZOFURAN TYPE DERIVATIVES, A COMPOSITION COMPRISING THE SAME FOR TREATING OR PREVENTING COGNITIVE DYSFUNCTION AND THE USE THEREOF - The present invention relates to the novel benzofuran derivatives, the preparation thereof and the composition comprising the same. The benzofuran derivatives of the present invention showed potent inhibiting activity of beta-amyloid aggregation and cell cytotoxicity resulting in stimulating the proliferation of neuronal cells as well as recovering activity of memory learning injury caused by neuronal cell injury using transformed animal model with beta-amyloid precursor gene, therefore the compounds can be useful in treating or preventing cognitive function disorder. | 09-27-2012 |
20120245166 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH - Methods for enhancing memory and/or learning and prevent neurodegeneration by administration of certain heterocyclic and aromatic compounds are described. The methods are particularly useful for treating patients suffering from a neurodegenerative disease such as (without limitation) Alzheimer's, Parkinsons's, Lou Gehrig's (ALS) disease or memory or learning impairment. A neuronal human cell-based assay that assess NF-kB gene up-regulation using a luciferase reporter is also provided that screens for compounds useful in methods for enhancing memory or learning. | 09-27-2012 |
20120302566 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS - The present invention relates to compounds defined by formula (I) | 11-29-2012 |
20130005722 | Pharmaceutical Composition of Mycophenolate Mofetil and Process for Preparing Thereof - The present invention is a pharmaceutical composition comprising mycophenolate mofetil in an amount of about 75 to about 200 mg/ml and a suspending agent(s) in an amount of less than 1 mg/ml, as a dry formulation suitable, when constituted with water, for forming a suspension for oral administration, where mg/ml represents concentration after constitution with water. | 01-03-2013 |
20130040947 | TRKB AGONISTS AND METHODS OF USE - Compounds and methods related to the activation of the TrkB receptor are provided. The methods include administering a 7,8-di-hydroxyflavone derivative with modified flavone or heterocyclic ring to a subject in need thereof. Methods and compounds for the treatment of disorders including neurologic disorders, neuropsychiatric disorders, and metabolic disorders (e.g., obesity) are provided. | 02-14-2013 |
20130109687 | METHODS OF TREATING HIV INFECTION: INHIBITION OF DNA DEPENDENT PROTEIN KINASE | 05-02-2013 |
20130158026 | CHROMENONE DERIVATIVES - The invention concerns chromenone derivatives of Formula I | 06-20-2013 |
20130172339 | SULFONAMIDE COMPOUNDS - A compound of formula (I), wherein A is S, O or a double bond, and L is a substituted thiazolyl, phenyl or pyridyl. The compound is useful for the treatment of inflammation and cancer. | 07-04-2013 |
20130196987 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS - The present invention provides compounds, methods for the synthesis thereof and methods for the use thereof in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis. | 08-01-2013 |
20130231338 | BENZOFURAN-2-SULFONAMIDES DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS - The present invention relates to novel benzofuran-2-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. | 09-05-2013 |
20130231339 | BENZOFURAN-2-SULFONAMIDES PYRIDINE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS - The present invention relates to novel benzofuran-2-sulfonamide pyridine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. | 09-05-2013 |
20130237536 | HETEROCYCLIC MODULATORS OF CANNABINOID RECEPTORS - Heterocyclic compounds which modulate cannabinoid receptors are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as modulators of cannabinoid receptors and processes for synthesizing these compounds are also described herein. | 09-12-2013 |
20140024645 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS - Phenoxy acetic acids and phenyl propionic acids and their use in treating type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, or obesity are provided herein. The present compounds are activators of PPARδ and may be useful for treating conditions mediated by the same. | 01-23-2014 |
20140057905 | CANCER DIAGNOSTICS, THERAPEUTICS, AND DRUG DISCOVERY ASSOCIATED WITH MACROPINOCYTOSIS - The present invention is directed to methods of inhibiting both proliferation and survival of cancer cells and for treating a subject having cancer. The present invention is further directed to methods of diagnosing cancer in a subject and identifying cancer therapeutics. | 02-27-2014 |
20140113897 | COMPOSITIONS AND METHODS FOR MODULATING THE ACTIVITY OF EPSTEIN-BARR NUCLEAR ANTIGEN 1 - The present invention embraces compounds that modulate the activity of Epstein-Barr Nuclear Antigen 1 (BBNA1) protein and use thereof in methods for treating latent Epstein-Barr virus infection. R | 04-24-2014 |
20140128387 | CERTAIN PROTEIN KINASE INHIBITORS - Disclosed herein are protein kinase inhibitors, more particularly novel pyrimidine derivatives and pharmaceutical compositions thereof, and method of use thereof. | 05-08-2014 |
20140135324 | Rapamycin Derivative or an Impdh Inhibitor for Treating Polycystic Kidney Disease - A method for treating polycystic kidney disease, comprising administering to a subject in need thereof a therapeutical effective amount of an inosine-5′-monophosphate dehydrogenase inhibitor or a rapamycin derivative. | 05-15-2014 |
20140163025 | INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS - The present invention relates to compounds of general formula I, | 06-12-2014 |
20140179695 | CHROMANE COMPOUNDS - The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing or treating diseases or conditions associated with and/or mediated by β-secretase activity, hydrolysis of a β-secretase site of a β-amyloid precursor protein, and/or β-amyloid protein accumulation, including a pharmaceutical composition for preventing or treating diseases including, but not limited to, Glaucoma, MCI (Mild cognitive impairment) or Alzheimer's disease, especially, Alzheimer's disease. | 06-26-2014 |
20140194419 | CHROMENONE DERIVATIVES - The invention concerns chromenone derivatives of Formula I | 07-10-2014 |
20140243329 | SULFAMIDES AS TRPM8 MODULATORS - Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows: | 08-28-2014 |
20140275068 | PRO-DRUG COMPOUNDS - The present invention provides neuronal gap junction blocking compounds according to formula (I) or a hydrate, solvate, or pharmaceutically acceptable salt thereof: | 09-18-2014 |
20140296232 | COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS - The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof: | 10-02-2014 |
20140303160 | Targeting GLI Proteins in Human Cancer by Small Molecules - The present disclosure provides compositions, pharmaceutical preparations and methods for the diagnosis and treatment of cancers expressing a GLI polypeptide. The disclosed compositions and pharmaceutical preparations may comprise one or more pyrazolyl-containing compounds, or an analog or derivative thereof. | 10-09-2014 |
20140329813 | BENZOFURAN-2-SULFONAMIDES PYRIDINE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS - The present invention relates to novel benzofuran-2-sulfonamide pyridine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. | 11-06-2014 |
20150038507 | Antiprotozoal Compounds - The invention is directed to a compound of formula I, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by administration of the compound, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of Human African Trypanosomiasis (HAT), Chagas disease, Leishmaniasis and malaria, the method comprising administering to a mammal, including a human, in need of such treatment a compound of formula I as described above. | 02-05-2015 |
20150038508 | TREATMENT OF LUPUS NEPHRITIS USING LAQUINIMOD - This invention provides a method of treating a subject afflicted with active lupus nephritis comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This invention also provides laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis. This invention further provides a pharmaceutical composition comprising an amount of laquinimod or pharmaceutically acceptable salt thereof for use in treating a subject afflicted with active lupus nephritis. | 02-05-2015 |
20150045358 | PHARMACEUTICAL COMPOSITION FOR TREATING DISORDERS ASSOCIATED WITH INSULIN RESISTANCE - A pharmaceutical composition for treating disorders associated with insulin resistance is disclosed, and the composition comprises at least one inhibitor which is an effective agent to suppress endothelin-1-stimulated resistin gene expression through decreasing the endothelin-1-stimulated phosphorylation of proteins downstream of endothelin type A receptor, wherein the downstream signaling molecules comprise ERK1/2, JNKs, AKT, and STAT3 proteins, and wherein the inhibitor is selected from at least one antagonist of the endothelin type A receptor or downstream signaling proteins. | 02-12-2015 |
20150051207 | USE OF UNSATURATED SPHINGOSINE COMPOUNDS AS CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER - The present invention is directed to unsaturated sphingosine compounds which are useful as therapeutic agents for the treatment of cancer and for the treatment of other diseases including diabetes and infection with intracellular bacteria. The invention is also directed to methods of using the compounds and pharmaceutical compositions comprising the compounds in treating these diseases. | 02-19-2015 |
20150111888 | SMALL COMPOUNDS TARGETING TACC3 - The present invention provides a small compound targeting at TACC3. The present invention further provides a drug, particularly, an anticancer agent, comprising the small compound targeting at TACC3. A compound represented by the general formula (I) or a pharmaceutically acceptable salt, solvate, or ester derivative thereof binds to TACC3 and inhibits cell growth. Thus, these compounds can be used as drugs, particularly, anticancer agents. | 04-23-2015 |
20150126507 | COMPOUNDS TO TREAT HEARING LOSS - The invention is directed, in part, to compounds of structure (I) | 05-07-2015 |
20150148343 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS - The present invention relates to novel sirtuin-modulating compounds, corresponding pharmaceutical compositions comprising a sirtuin-modulating compound, alone and/or in combination with another therapeutic agent, and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. | 05-28-2015 |
20150299181 | POLYCYCLIC HERG ACTIVATORS - The present invention provides a compound of formula I, in which R | 10-22-2015 |
20160016929 | PRO-DRUG COMPOUNDS - A compound according to formula (I) or a hydrate, solvate, or pharmaceutically acceptable salt thereof: wherein where the integers Q, R | 01-21-2016 |
20160022690 | COMBINATION TREATMENT - The present invention relates to the use of combinations comprising 8-[(1R)-1-(3,5-difluorophenylamino)ethyl]-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide or a pharmaceutically acceptable salt thereof and a taxane in the treatment or prophylaxis of cancer; pharmaceutical compositions comprising Compound [I] (or a pharmaceutically acceptable salt thereof) and a taxane; kits comprising Compound [I] or a pharmaceutically acceptable salt thereof and a taxane, optionally with instructions for use; and methods of treatment comprising the simultaneous, sequential or separate administration of Compound [I] or a pharmaceutically acceptable salt thereof and a taxane to warm-blooded animal, such as man. | 01-28-2016 |
20160022691 | TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH - Methods for enhancing memory and/or learning and prevent neurodegeneration by administration of certain heterocyclic and aromatic compounds are described. The methods are particularly useful for treating patients suffering from a neurodegenerative disease such as (without limitation) Alzheimer's, Parkinsons's, and Lou Gehrig's (ALS) disease or memory or learning impairment. A neuronal human cell-based assay that assess NF-kB gene up-regulation using a luciferase reporter is also provided that screens for compounds useful in methods for enhancing memory or learning. | 01-28-2016 |
20160052918 | SMALL COMPOUNDS TARGETING TACC3 - The present invention provides a small compound targeting at TACC3. The present invention further provides a drug, particularly, an anticancer agent, comprising the small compound targeting at TACC3. A compound represented by the general formula (I) or a pharmaceutically acceptable salt, solvate, or ester derivative thereof binds to TACC3 and inhibits cell growth. Thus, these compounds can be used as drugs, particularly, anticancer agents. | 02-25-2016 |
20160108025 | POLYCYCLIC HERG ACTIVATORS - The present invention provides a compound of formula I, in which R | 04-21-2016 |
20160108056 | HETEROCYCLIC DERIVATIVES AND USE THEREOF - A heterocyclic derivative represented by formula (I), or a pharmaceutically acceptable salt or a stereoisomer thereof, which has an inhibitory effect on the activation of STAT3 protein, and is useful for the prevention or treatment of diseases associated with the activation of STAT3 protein. | 04-21-2016 |
20160168144 | COMPOSITIONS AND METHODS FOR MODULATING THE ACTIVITY OF EPSTEIN-BARR NUCLEAR ANTIGEN 1 | 06-16-2016 |